Paul R. Buckley

Paul R. Buckley

Auto-generated profile, based on publicly available information

Paul R. Buckley

MRC Human Immunology Unit, Medical Research Council (MRC) Weatherall Institute of Molecular Medicine (WIMM), John Radcliffe Hospital, University of Oxford, Oxford, UK

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2022 in Immunology
Verified
Journal Article
Open access
PDF file
PBPaul R. Buckley
Paul R. Buckley
CLChloe H. Lee
Chloe H. Lee
MPMariana Pereira Pinho
Mariana Pereira Pinho
RBRosana Ottakandathil Babu
Rosana Ottakandathil Babu
JWJeongmin Woo
Jeongmin Woo
HKHashem Koohy
Hashem Koohy
The conditions and extent of cross-protective immunity between SARS-CoV-2 and common-cold human coronaviruses HCoVs remain open despite several reports of pre-existing T cell immunity to SARS-CoV-2 in individuals without prior exposure. Using a pool of functionally evaluated SARS-CoV-2 peptides, we report a map of 126 immunogenic peptides with high similarity to 285 MHC-presented peptides from at least one HCoV. Employing this map of SARS-CoV-2-non-homologous and homologous immunogenic peptides, we observe several immunogenic peptides with high similarity to human proteins, some of which have been reported to have elevated expression in severe COVID-19 patients. After combining our map with SARS-CoV-2-specific TCR repertoire data from COVID-19 patients and healthy controls, we show that public repertoires for the majority of convalescent patients are dominated by TCRs cognate to non-homologous SARS-CoV-2 peptides. We find that for a subset of patients, >50% of their public SARS-CoV-2-specific repertoires consist of TCRs cognate to homologous SARS-CoV-2-HCoV peptides. Further analysis suggests that this skewed distribution of TCRs cognate to homologous or non-homologous peptides in COVID-19 patients is likely to be HLA-dependent. Finally, we provide 10 SARS-CoV-2 peptides with known cognate TCRs that are conserved across multiple coronaviruses and are predicted to be recognised by a high proportion of the global population. These findings may have important implications for COVID-19 heterogeneity, vaccine-induced immune responses, and robustness of immunity to SARS-CoV-2 and its variants.

13 September 2023 in Genome Medicine
Verified
Journal Article
Open access
PDF file
CLChloe H. Lee
Chloe H. Lee
JHJaesung Huh
Jaesung Huh
PBPaul R. Buckley
Paul R. Buckley
MJMyeongjun Jang
Myeongjun Jang
MPMariana Pereira Pinho
Mariana Pereira Pinho
HKHashem Koohy
Hashem Koohy
Background: T-cells play a crucial role in the adaptive immune system by triggering responses against cancer cells and pathogens, while maintaining tolerance against self-antigens, which has sparked interest in the development of various T-cell-focused immunotherapies. However, the identification of antigens recognised by T-cells is low-throughput and laborious. To overcome some of these limitations, computational methods for predicting CD8 + T-cell epitopes have emerged. Despite recent developments, most immunogenicity algorithms struggle to learn features of peptide immunogenicity from small datasets, suffer from HLA bias and are unable to reliably predict pathology-specific CD8 + T-cell epitopes.Methods: We developed TRAP (T-cell recognition potential of HLA-I presented peptides), a robust deep learning workflow for predicting CD8 + T-cell epitopes from MHC-I presented pathogenic and self-peptides. TRAP uses transfer learning, deep learning architecture and MHC binding information to make context-specific predictions of CD8 + T-cell epitopes. TRAP also detects low-confidence predictions for peptides that differ significantly from those in the training datasets to abstain from making incorrect predictions. To estimate the immunogenicity of pathogenic peptides with low-confidence predictions, we further developed a novel metric, RSAT (relative similarity to autoantigens and tumour-associated antigens), as a complementary to ‘dissimilarity to self’ from cancer studies.Results: TRAP was used to identify epitopes from glioblastoma patients as well as SARS-CoV-2 peptides, and it outperformed other algorithms in both cancer and pathogenic settings. TRAP was especially effective at extracting immunogenicity-associated properties from restricted data of emerging pathogens and translating them onto related species, as well as minimising the loss of likely epitopes in imbalanced datasets. We also demonstrated that the novel metric termed RSAT was able to estimate immunogenic of pathogenic peptides of various lengths and species. TRAP implementation is available at:https://github.com/ChloeHJ/TRAP.Conclusions: This study presents a novel computational workflow for accurately predicting CD8 + T-cell epitopes to foster a better understanding of antigen-specific T-cell response and the development of effective clinical therapeutics.

1 December 2021 in ImmunoInformatics
Verified
Journal Article
Open access
CLChloe H. Lee
Chloe H. Lee
AAAgne Antanaviciute
Agne Antanaviciute
PBPaul R. Buckley
Paul R. Buckley
ASAlison Simmons
Alison Simmons
HKHashem Koohy
Hashem Koohy

20 July 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
PBPaul R. Buckley
Paul R. Buckley
CLChloe H. Lee
Chloe H. Lee
MPMariana Pereira Pinho
Mariana Pereira Pinho
RBRosana Ottakandathil Babu
Rosana Ottakandathil Babu
JWJeongmin Woo
Jeongmin Woo
HKHashem Koohy
Hashem Koohy
Pre-existing T cell immunity to SARS-CoV-2 in individuals without prior exposure to SARS-CoV-2 has been reported in several studies. While emerging evidence hints toward prior exposure to common-cold human coronaviruses (HCoV), the extent of- and conditions for-cross-protective immunity between SARS-CoV-2 and HCoVs remain open. Here, by leveraging a comprehensive pool of publicly available functionally evaluated SARS-CoV-2 peptides, we report 126 immunogenic SARS-CoV-2 peptides with high sequence similarity to 285 MHC-presented target peptides from at least one of four HCoV, thus providing a map describing the landscape of SARS-CoV-2 shared and private immunogenic peptides with functionally validated T cell responses. Using this map, we show that while SARS-CoV-2 immunogenic peptides in general exhibit higher level of dissimilarity to both self-proteome and -microbiomes, there exist several SARS-CoV-2 immunogenic peptides with high similarity to various human protein coding genes, some of which have been reported to have elevated expression in severe COVID-19 patients. We then combine our map with a SARS-CoV-2-specific TCR repertoire data from COVID-19 patients and healthy controls and show that whereas the public repertoire for the majority of convalescent patients are dominated by TCRs cognate to private SARS-CoV-2 peptides, for a subset of patients, more than 50% of their public repertoires that show reactivity to SARS-CoV-2, consist of TCRs cognate to shared SARS-CoV-2-HCoV peptides. Further analyses suggest that the skewed distribution of TCRs cognate to shared and private peptides in COVID-19 patients is likely to be HLA-dependent. Finally, by utilising the global prevalence of HLA alleles, we provide 10 peptides with known cognate TCRs that are conserved across SARS-CoV-2 and multiple human coronaviruses and are predicted to be recognised by a high proportion of the global population. Overall, our work indicates the potential for HCoV-SARS-CoV-2 reactive CD8 + T cells, which is likely dependent on differences in HLA-coding genes among individuals. These findings may have important implications for COVID-19 heterogeneity and vaccine-induced immune responses as well as robustness of immunity to SARS-CoV-2 and its variants.

27 February 1994
Verified
Conference Paper
Closed access
PBP. Buckley
P. Buckley
BPB. Placzankis
B. Placzankis
JBJ. Beatty
J. Beatty
Richard J C BrownRichard J C Brown
Richard J C Brown
The hydrogen embrittlement characterization of UNS G43406 and UNS K92580 was conducted using a rising step load bend test and potentiodynamic scans. A relationship between KIscc and open circuit potentials of these steels at similar hardnesses was shown. Potentiodynamic scans were used to explain this relationship in light of the hydrogen ion reaction in acidified environments. Methods for the mitigation of hydrogen embrittlment in high strength steels are discussed.

29 December 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
CLChloe H. Lee
Chloe H. Lee
JHJaesung Huh
Jaesung Huh
PBPaul R. Buckley
Paul R. Buckley
MJMyeongjun Jang
Myeongjun Jang
MPMariana Pereira Pinho
Mariana Pereira Pinho
HKHashem Koohy
Hashem Koohy
T-cells play a crucial role in the adaptive immune system by inducing an anti-tumour response, defending against pathogens, and maintaining tolerance against self-antigens, which has sparked interest in the development of T-cell-based vaccines and immunotherapies. Because screening antigens driving the T-cell response is currently low-throughput and laborious, computational methods for predicting CD8+ T-cell epitopes have emerged. However, most immunogenicity algorithms struggle to learn features of peptide immunogenicity from small datasets, suffer from HLA bias and are unable to reliably predict pathology-specific CD8+ T-cell epitopes. Therefore, we developed TRAP (T-cell recognition potential of HLA-I presented peptides), a robust deep learning platform for predicting CD8+ T-cell epitopes from MHC-I presented pathogenic and self-peptides. TRAP uses transfer learning, deep learning architecture and MHC binding information to make context-specific predictions of CD8+ T-cell epitopes. TRAP also detects low-confidence predictions for peptides that differ significantly from those in the training datasets to abstain from making incorrect predictions. To estimate the immunogenicity of pathogenic peptides with low-confidence predictions, we further developed a novel metric, RSAT (relative similarity to autoantigens and tumour-associated antigens), as a complementary to ‘dissimilarity to self’ from cancer studies. We used TRAP to identify epitopes from glioblastoma patients as well as SARS-CoV-2 peptides, and it outperformed other algorithms in both cancer and pathogenic settings. Thus, this study presents a novel computational platform for accurately predicting CD8+ T-cell epitopes to foster a better understanding of antigen-specific T-cell response and the development of effective clinical therapeutics. Highlights HLA bias and out-of-distribution problem are causes of poor performance of current state-of-the-art algorithms Transfer learning, deep learning architecture, context-specific and HLA-generalised approaches improve CD8+ T-cell epitope prediction TRAP reports degree of correctness to improve reliability of the prediction A novel metric termed RSAT estimates immunogenicity of pathogenic peptides, as a complementary to ‘dissimilarity to self’ from cancer studies